- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01316952
Coreg and HSRs-Updated Analysis
April 14, 2015 updated by: GlaxoSmithKline
A Nested Case-control Study of the Association Between Coreg IR and Coreg CR and Hypersensitivity Reactions: Anaphylactic Reaction/Angioedema-Updated Analysis
A cluster of reports of hypersensitivity reactions among patients who switched from carvedilol (immediate release formulation, referred to hereafter as carvedilol) to carvedilol extended release was received during the initial post-launch period of carvedilol extended release.
In follow up to this observation, product labeling for both agents was updated and a nested case control study was subsequently conducted to examine the risk of serious hypersensitivity reactions i.e. anaphylactic reaction and/or angioedema among patients who used carvedilol extended release compared to carvedilol and separately compared to other long acting beta(β)-blockers.
This proposed analysis is an update to the previously conducted analysis using the same database, LabRx, now containing 2 additional years of data, which should provide a larger number of carvedilol extended release exposed subjects.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Derived from the LabRx database from Oct. 1st 2004 to Sep. 30th 2009.
The LabRx Database (referred to in publications as the "i3 InVision Data Mart") is provided by Ingenix Pharmaceutical Services, Inc.
It is a comprehensive, de-identified U.S. healthcare claims database that contains the aggregated health claims experience of the covered lives managed by United Healthcare.
It contains only those covered lives for which there exists a combined benefit structure including medical and prescription coverage.
Overall, it is representative of the non-elderly, insurance-carrying population in the U.S., but it also contains information on several hundred thousand Managed Medicaid and Medicare Advantage members.
It contains inpatient, outpatient and pharmacy claims, lab results and enrolment information on over 30.5 million lives from October 2004 through September 2009.
Description
Inclusion Criteria:
- At least one prescription claim for a β-blocker during follow-up time available in the database.
- At least one month of enrollment in the healthcare plan
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
LabRx database Oct. 1st 2004 to Sep. 30th 2009
The study cohort from which cases and controls are drawn is all subjects in the LabRx database between Oct. 1st 2004 to Sep. 30th 2009.
|
All dosages of carvedilol immediate release
All dosages of carvedilol extended release
All dosages of LA propranolol and SA metoprolol
i.e., labetalol.
All dosages.
Excluding carvedilol immediate release and carvedilol extended release.
All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
No β-blocker within the month prior to the index date
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hypersensitivity reactions (anaphylactic reaction/ angioedema)
Time Frame: Hypersensitivity reactions among users in the LabRx database between Oct. 1st 2004 to Sep. 30th 2009
|
Hypersensitivity reactions among users in the LabRx database between Oct. 1st 2004 to Sep. 30th 2009
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2010
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
March 1, 2011
Study Registration Dates
First Submitted
March 15, 2011
First Submitted That Met QC Criteria
March 15, 2011
First Posted (Estimate)
March 16, 2011
Study Record Updates
Last Update Posted (Estimate)
April 15, 2015
Last Update Submitted That Met QC Criteria
April 14, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Hypersensitivity
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Protective Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Antioxidants
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Carvedilol
- Adrenergic Agents
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
Other Study ID Numbers
- 114522
- WEUSRTP4862 (Other Identifier: GSK)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypersensitivity
-
National Institute of Allergy and Infectious Diseases...Consortium of Food Allergy ResearchCompletedMilk Hypersensitivity | Egg Hypersensitivity | Food Hypersensitivity | Peanut HypersensitivityUnited States
-
Ospedale Buon Consiglio FatebenefratelliCompleted- Egg HypersensitivityItaly
-
National Institute of Allergy and Infectious Diseases...Consortium of Food Allergy ResearchCompletedHypersensitivity | Food Hypersensitivity | Peanut Hypersensitivity | Immediate HypersensitivityUnited States
-
Johns Hopkins UniversityCompletedFood Hypersensitivity | Peanut Hypersensitivity | Immediate HypersensitivityUnited States
-
Allertein Therapeutics, LLCConsortium of Food Allergy ResearchCompletedHypersensitivity | Food Hypersensitivity | Peanut Hypersensitivity | Immediate HypersensitivityUnited States
-
IRCCS Burlo GarofoloCompleted
-
Alton MeltonThe Cleveland ClinicActive, not recruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)Completed
-
National Institute of Allergy and Infectious Diseases...Consortium of Food Allergy ResearchCompletedHypersensitivity | Food Hypersensitivity | Hypersensitivity, Immediate | Peanut HypersensitivityUnited States
-
University of North Carolina, Chapel HillGenentech, Inc.CompletedPeanut HypersensitivityUnited States
Clinical Trials on Carvedilol immediate release only
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
GlaxoSmithKlineQuotient ClinicalCompletedAutoimmune DiseasesUnited Kingdom
-
GlaxoSmithKlineQuotient SciencesCompletedAutoimmune DiseasesUnited Kingdom
-
Heptares Therapeutics LimitedQuotient ClinicalCompletedAlzheimer's DiseaseUnited Kingdom
-
PfizerCompleted
-
PfizerCompletedHealthy ParticipantsBelgium
-
University of LuebeckEuropean Commission; Deutsche Stiftung für Herzforschung; Deutsches Zentrum für... and other collaboratorsCompletedComplications | Acute Myocardial Infarction | Cardiogenic ShockGermany
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2 | Type 2 Diabetes MellitusUnited States
-
CTI-1, LLCGlaxoSmithKline; CTI Clinical Trial and Consulting ServicesCompletedCongestive Heart FailureUnited States
-
PfizerCompletedHealthy SubjectsUnited States